Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2021-02-02 Major Shareholding Noti…
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-02 English
FORM 4 SUBMISSION
Director's Dealing
2021-01-21 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and prospectus related to a public offering of common stock by Protagonist Therapeutics, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of filing is related to capital raising activities and provides detailed information about the securities being offered to investors. It is not an annual report, earnings release, management discussion, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms and underwriting information, confirming it is a financing update rather than a brief announcement or regulatory filing.
2020-12-12 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common stock, including details about the number of shares, pricing, underwriters, and expected gross proceeds. It also references exhibits such as the underwriting agreement and legal opinion. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is not a full financial report but an announcement of a financing event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6175 characters, which is sufficient to contain substantive information about the financing event rather than just a brief announcement or a certification. Hence, the classification is CAP with high confidence.
2020-12-11 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and accompanying prospectus for a common stock offering by Protagonist Therapeutics, Inc. It includes sections such as 'Prospectus Supplement Summary', 'Risk Factors', 'Use of Proceeds', 'Capitalization', and detailed descriptions of the company's business and pipeline. The presence of terms like 'prospectus supplement', 'offering of common stock', 'use of proceeds', and 'underwriting' clearly indicate this is a capital raising document. The form type '424B5' is a SEC filing form used for prospectus supplements related to securities offerings. This matches the definition of a Capital/Financing Update (CAP) which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, nor an earnings release or management discussion. It is not a regulatory filing unrelated to financing, nor a proxy or governance document. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2020-12-10 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common stock, preferred stock, debt securities, and warrants. The document includes a prospectus describing the securities to be offered and the terms of the offering. This type of filing is related to capital raising activities and financing updates rather than financial performance reports, management changes, or other categories. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual registration statement and prospectus. Hence, the classification is CAP with high confidence.
2020-12-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.